

### REMARKS

Claims 1-11 and 22 are pending in the current applications. Claims 1-11 have been allowed. Claim 22 is rejected. No amendments to the claims have been made in the current paper. Applicants thank the Examiner for allowing claims 1-11.

Claim 22 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over the claim[s] 11 of U.S. Patent No. 6,699,887 B2.

A terminal disclaimer in compliance with 37 CFR §1.321(c) may be used to overcome the rejection based on a nonstatutory double patenting ground providing the conflicting patent is shown to be commonly owned with this application. A terminal disclaimer has been filed herewith. The assignee of U.S. No. 6,699,887, Hoffmann-La Roche Inc., and the assignee of the instant application, Roche Palo Alto LLC, are under common ownership and control.

### CONCLUSION

With the submission of the terminal disclaimer all pending claims are believed to be in condition for allowance and issuance of a notice of allowance is respectfully requested. The Examiner is authorized to deduct the fee for a one month extension under 37 CFR 1.17(a)(1) and the fee for a terminal disclaimer under 37 CFR 1.20(d) from deposit account 18-1700. No other fees are believed to be due with this submission but in the event that a fee is required the Examiner is authorized to deduct it from the deposit account. If the Examiner believes a telephone conference will expedite the prosecution of this application, the Examiner is invited to contact the undersigned at the number indicated below.

Respectfully submitted,



By: Brian L. Buckwalter  
Registration No. 46,585  
Agent for Applicant

August \_\_, 2006  
Roche Palo Alto LLC  
3431 Hillview Avenue,  
Palo Alto, CA 94304-1397  
Telephone 650-855-6995  
Telecopier 650-855-5322

#141656 v1

11

R0204C-DIV